Contribution of P4-P3′ Residues Surrounding P1 Residues Arg336 and Arg562 in the Activated Protein C-Catalyzed Inactivation of Factor VIIIa.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1693-1693
Author(s):  
Fatbardha Varfaj ◽  
Hironao Wakabayashi ◽  
Philip J. Fay

Abstract The essential role of factor VIII in blood coagulation is evident from the bleeding diathesis hemophilia A, which results from a deficiency or defect in factor VIII. Activated factor VIII (factor VIIIa) serves as a cofactor for factor IXa in the factor Xase complex, which activates factor X during the propagation phase of coagulation. Factor VIIIa is a non-covalent heterotrimer consisting of A1, A2 and A3–C1–C2 subunits. Down-regulation of factor Xase is achieved by cofactor inactivation and is thought to occur by a non-proteolytic mechanism involving dissociation of the A2 subunit as well as a proteolytic mechanism catalyzed by activated protein C (APC). APC cleaves the P1 residues Arg336 near the C-terminus of the A1 subunit and Arg562 bisecting the A2 subunit. We recently demonstrated that these cleavages occur in an independent non-sequential fashion, with residue Arg336 being cleaved at a rate ~25-fold faster than Arg562 (Varfaj et al., Biochem J. 2006). While substantial evidence implicates involvement of exosite-directed interactions in the catalytic mechanism of APC, another factor that may contribute to the disparate cleavage rates are residues surrounding the P1 Arg residues. To examine the roles of these sequences in cofactor cleavage, we prepared two factor VIII mutants where the P2–P4 and P1′–P3′ residues surrounding Arg336 (Pro-Gln-Leu and Met-Lys-Asn, respectively) were replaced with those residues surrounding Arg562 (Val-Asp-Gln and Gly-Asn-Gln, respectively), and designated Arg336P2-P4A2 and Arg336P1′-P3′A2. In addition, a single mutant was prepared where the P4-P3′ residues surrounding Arg562 were replaced with those residues surrounding Arg336, and designated Arg562P4-P3′A1. Recombinant, B-domainless factor VIII proteins were stably expressed in BHK cells and purified. Specific activity values measured for Arg336P2-P4A2 and Arg336P1′-P3′A2 mutants were similar to that of wild type (WT) factor VIII, whereas Arg562P4-P3′A1 showed a specific activity value <1% that of WT factor VIII. This latter observation was consistent with the substitution of the A1 residues altering the factor IXa-interactive site contained within A2 residues 558–565. Western blot analysis examining the rates of APC-catalyzed cleavage at Arg336 showed an ~60-fold reduction for the Arg336P2-P4A2 mutant and an ~10-fold reduction for Arg336P1′-P3′A2 mutant compared to cleavage rates observed for WT factor VIIIa. Rates of cleavage at the Arg562 site in these mutants were similar to the WT protein at this site. These results suggest that the native sequence surrounding Arg336 possesses residues more optimal for cleavage by APC than those that surround Arg562 in the A2 subunit. Examination of the Arg562P4-P3′A1 mutant showed a modest increase (~2-fold) in cleavage rate at Arg562, whereas cleavage at the Arg336 was similar to the WT control. Overall, these results suggest a relatively minor role for specific sequences in the cleavage mechanism for APC at the A2 site, whereas a more dominant role for sequence specificity appears necessary for efficient proteolysis at the A1 site, which represents the primary site of attack by APC.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2689-2689
Author(s):  
Fatbardha Varfaj ◽  
Jennifer DeAngelis ◽  
Hironao Wakabayashi ◽  
Philip J. Fay

Abstract Activated Protein C (APC) is an anticoagulant serine protease that proteolytically inactivates the coagulation cofactors, factors (F) Va and VIIIa. FVIIIa is a non-covalent heterotrimer consisting of A1, A2 and A3-C1-C2 subunits. APC-catalyzed inactivation of FVIIIa results from proteolysis at the P1 residues Arg336 and Arg562 within the A1 and A2 subunits, respectively, with cleavage at Arg336 representing the dominant reaction. We recently showed that replacement of the P4-P3′ residues surrounding the Arg336 site with the corresponding residues flanking Arg562 resulted in an ∼100-fold reduction in cleavage rate at Arg336 (Varfaj et al, J. Biol. Chem.2007). Comparison of the P4-P3′ residues at the slow-reacting site in FVIIIa (Arg562) with the corresponding residues at the fast-reacting site in FVa (Arg506) revealed that these sequences differ primarily at the P2 and P2′ positions. This observation suggested an important contribution by these residues to cleavage efficiency. The role of the P2 and P2′ residues in the proteolysis of FVIIIa by APC was investigated by preparing recombinant FVIII proteins possessing mutations at Leu335 (P2) and Lys338 (P2′) flanking the P1 Arg336. B-domainless FVIII proteins were stably expressed in BHK cells and purified. Leu335Arg and Leu335Gln mutants were constructed based upon the P2 residues preceding Arg506 in FVa and Arg562 in FVIIIa, respectively. The Lys338Ile mutant was based upon the P2′ residue following Arg506 in FVa. Specific activity values for all FVIII variants were similar to wild type (WT) FVIII. APC-catalyzed inactivation rates for FVIIIa were determined using a FXa generation assay, and rates for proteolysis at the scissile bonds within the A1 and A2 subunits were determined by SDS-PAGE and Western blotting. Rates for APC-catalyzed cleavage of the A1 subunit for the FVIIIa variants Leu335Arg and Leu335Gln were reduced ∼2- and ∼4-fold, respectively, as compared to WT. However, the rate of cleavage of the A1 subunit in the Lys338Ile FVIIIa variant was enhanced ∼3-fold compared to WT. Cleavage rates at Arg562 in all the variants were unaffected by mutation at either residue 335 or 338. These relative values for rates of proteolysis paralleled the observed rates for inactivation of the FVIIIa forms. Overall, these results suggest that both P2 and P2′ residues are important in the efficient proteolysis at Arg336 in FVIIIa. Furthermore, Leu appears more optimal than either Arg or Gln at the P2 position, whereas Ile is preferred over Lys at the P2′ position in this macromolecular substrate for APC.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2684-2684
Author(s):  
Masahiro Takeyama ◽  
Keiji Nogami ◽  
Tetsuhiro Soeda ◽  
Akira Yoshioka ◽  
Midori Shima

Abstract Protein S functions as a cofactor of activated protein C that inactivates factor VIII(a) and factor V(a). We recently have reported a new regulatory mechanism that protein S interacted with both the A2 and A3 domains in factor VIII, and consequently this cofactor directly impaired the factor Xase complex by competing the interaction of factor IXa to factor VIIIa (Blood2006; 108, 487a). Since factor IXa blocked the binding of A2 subunit to protein S, we attempted several approaches to localize the protein S-interactive site(s) on the factor VIII A2 domain. An anti-A2 monoclonal antibody (mAb413) with the 484–509 epitope, recognizing a factor IXa-interactive site on the A2, inhibited the A2 binding to immobilized protein S up to approximately 90% in a dose-dependent manner in a surface plasmon resonance-based assay. Furthermore, ELISA-based assay showed that a synthetic peptide corresponding to residues 484–509 directly bound to protein S dose-dependently. Covalent cross-linking was observed between the 484–509 peptide and protein S following reaction with EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide) using SDS-PAGE. The cross-linked product formed with EDC was consistent with 1:1 stoichiometry of reactants, suggesting specificity in the 484–509 peptide and protein S interaction. This cross-linking formation was blocked by the addition of the 484–497 peptide, whilst not by the 498–509 peptide, supporting the presence of protein S-interactive site within residues 484–497. Furthermore, N-terminal sequence analysis of the 484–509 peptide-protein S product showed that three sequential basic residues (S488, R489 and R490) could not be detected, supporting that three residues participate in cross-link formation. To confirm the significance of these residues in A2 domain for protein S-binding, the mutant forms of the A2 domain, converted to alanine, were expressed in baculovirus system and purified. Compared with wild type A2 (Kd: ∼9 nM), each binding affinity of S488A, R489A, or R490A A2 mutant for protein S was decreased by 4∼5-fold (32, 40 and 40 nM, respectively). These results indicate that the 484–509 region in the factor VIII A2 domain, and in particular a cluster of basic amino acids at residues 488–490, contributes to a unique protein S-interactive site.


1984 ◽  
Vol 125 (1) ◽  
pp. 177-183 ◽  
Author(s):  
Rogier M. Bertina ◽  
Rosemiek Cupers ◽  
Aat van Wijngaarden

1994 ◽  
Vol 269 (13) ◽  
pp. 9445-9452
Author(s):  
L.M. Regan ◽  
B.J. Lamphear ◽  
C.F. Huggins ◽  
F.J. Walker ◽  
P.J. Fay

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1692-1692
Author(s):  
Jennifer Newell ◽  
Philip J. Fay

Abstract Factor VIIIa serves as an essential cofactor for the factor IXa-catalyzed activation of factor X during the propagation phase of coagulation. The factor VIII procofactor is converted to factor VIIIa by thrombin-catalyzed proteolysis of three P1 positions at Arg372 (A1–A2 junction), Arg740 (A2–B junction), and Arg1689 (a3–A3 junction). Cleavage at Arg372 exposes a cryptic functional factor IXa-interactive site, while cleavage at Arg1689 liberates factor VIII from von Willebrand factor and contributes to factor VIIIa specific activity, thus making both sites essential for procofactor activation. However, cleavage at Arg740, separating the A2–B domainal junction, has not been rigorously studied. To evaluate thrombin cleavage at Arg740, we prepared and stably expressed two recombinant factor VIII mutants, Arg740His and Arg740Gln. Results from a previous study examining proteolysis at Arg372 revealed substantially reduced cleavage rates following substitution of that P1 Arg with His, whereas replacing Arg with Gln at residue 372 yielded an uncleavable bond at that site (Nogami et al., Blood, 2005). Specific activity values for the factor VIII Arg740His and Arg740Gln variants as measured using a one-stage clotting assay were approximately 50% and 18%, respectively, that of the wild type protein. SDS-PAGE and western blotting following a reaction of factor VIII Arg740His with thrombin showed reduced rates of cleavage at His740 as well as at Arg372 relative to the wild type. Alternatively, factor VIII Arg740Gln was resistant to thrombin cleavage at Gln740 and showed little, if any, cleavage at Arg372 over an extended time course. The mutant proteins assayed in a purified system by factor Xa generation showed a slight increase in activity for the Arg740His variant compared with the Arg740Gln variant in both the absence and presence of thrombin, and the activities for both variants were reduced compared with wild type factor VIII. These results suggest that cleavage at residue 740 affects subsequent cleavage at Arg372 and generation of the active cofactor factor VIIIa. Preliminary results obtained evaluating proteolysis of these mutants by factor Xa, which cleaves the same sites in factor VIII as thrombin, also revealed slow proteolysis at the P1 His and no cleavage at the P1 Gln. However, subsequent cleavage at Arg372 exhibited less dependence on initial cleavage at residue 740. These observations may explain the higher than predicted specific activity values obtained for the two variants and suggest a different mechanism of action for the two activating proteinases. Overall, these results support a model whereby cleavage of factor VIII heavy chain by thrombin is an ordered pathway with initial cleavage at Arg740 required to facilitate cleavage at the critical Arg372 site to yield the active cofactor.


1992 ◽  
Vol 176 (1) ◽  
pp. 27-35 ◽  
Author(s):  
M P McGee ◽  
L C Li ◽  
M Hensler

Generation of coagulation factor Xa by the intrinsic pathway protease complex is essential for normal activation of the coagulation cascade in vivo. Monocytes and platelets provide membrane sites for assembly of components of this protease complex, factors IXa and VIII. Under biologically relevant conditions, expression of functional activity by this complex is associated with activation of factor VIII to VIIIa. In the present studies, autocatalytic regulatory pathways operating on monocyte and platelet membranes were investigated by comparing the cofactor function of thrombin-activated factor VIII to that of factor Xa-activated factor VIII. Reciprocal functional titrations with purified human factor VIII and factor IXa were performed at fixed concentrations of human monocytes, CaCl2, factor X, and either factor IXa or factor VIII. Factor VIII was preactivated with either thrombin or factor Xa, and reactions were initiated by addition of factor X. Rates of factor X activation were measured using chromogenic substrate specific for factor Xa. The K1/2 values, i.e., concentration of factor VIIIa at which rates were half maximal, were 0.96 nM with thrombin-activated factor VIII and 1.1 nM with factor Xa-activated factor VIII. These values are close to factor VIII concentration in plasma. The Vsat, i.e., rates at saturating concentrations of factor VIII, were 33.3 and 13.6 nM factor Xa/min, respectively. The K1/2 and Vsat values obtained in titrations with factor IXa were not significantly different from those obtained with factor VIII. In titrations with factor X, the values of Michaelis-Menten coefficients (Km) were 31.7 nM with thrombin-activated factor VIII, and 14.2 nM with factor Xa-activated factor VIII. Maximal rates were 23.4 and 4.9 nM factor Xa/min, respectively. The apparent catalytic efficiency was similar with either form of factor VIIIa. Kinetic profiles obtained with platelets as a source of membrane were comparable to those obtained with monocytes. These kinetic profiles are consistent with a 1:1 stoichiometry for the functional interaction between cofactor and enzyme on the surface of monocytes and platelets. Taken together, these results indicate that autocatalytic pathways connecting the extrinsic, intrinsic, and common coagulation pathways can operate efficiently on the monocyte membrane.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1739-1739
Author(s):  
Fatbardha Varfaj ◽  
Julie Neuberg ◽  
Hironao Wakabayashi ◽  
Philip J. Fay

Abstract Activated Protein C (APC) is an anticoagulant serine protease that proteolytically inactivates cofactors Va and VIIIa. Cleavage of human factor VIIIa occurs at Arg336 and Arg562 located within the A1 and A2 subunits, respectively. While cleavages are not ordered, the former site appears to represent a preferred cleavage site. Efficient catalysis requires binding of APC to a phospholipid surface and to the A3-C1-C2 subunit of factor VIIIa. The latter observation suggests that APC likely binds substrate via an exosite(s) thereby contributing to substrate specificity. A study was undertaken to evaluate contributions of substrate docking at the active site and exosite tethering to the APC catalytic mechanism. Recombinant, human factor VIII mutants where P1 Arg residues at 336 and 562 were substituted with Ala or Gln were constructed and stably expressed. Purified factor VIII was converted to factor VIIIa by thrombin and used as substrate to elucidate the mechanism of cleavages. Proteins mutated at Arg336 were also mutated at Lys338 because the latter residue may serve as an alternative APC cleavage site when residue 336 is mutated. Rates of inactivation of wild type and mutant factor VIIIa molecules and rates of cleavage at Arg336 and Arg562 by APC were monitored in the presence and absence of protein S. The R336A/K338A mutant was inactivated and cleaved at the 336 site approximately 20-fold slower than the wild type, whereas the R336Q/K338Q mutant was completely resistant to cleavage at the 336 site. These results indicate that residues other than Arg may be tolerated at the P1 site, whereas Gln yields a cleavage-resistant substrate. Indeed, the R336Q/K338Q/R562Q (triple Q) mutant was resistant to cleavage at both P1 sites. Furthermore, mutations retarding cleavage at residue 336 showed a dramatic decrease in rates of inactivation suggesting that cleavage at this site correlated with the inactivation of factor VIIIa. The importance of exosite interactions was explored by inhibition experiments examining the inactivation of wild type factor VIIIa in the presence of triple Q mutant factor VIIIa. Wild type factor VIIIa inactivation rates decreased as the proportion of triple Q factor VIIIa increased, indicating that the P1 mutant factor VIIIa effectively sequestered APC from the native substrate. Evaluation of inactivation rates suggested that APC possessed an ~8-fold greater affinity for the triple Q FVIIIa than the wild type factor VIIIa. Consistent with that observation, the Ki for triple Q factor VIIIa (29.5 ± 3.6 nM) was ~5-fold less than the Km for wild type factor VIIIa (133 ± 27 nM). Taken together, these results indicate that mutations in the P1 site that prevent cleavage may also retard dissociation of the enzyme-substrate complex. Overall, results from this study suggest that exosite interactions make a primary contribution to substrate affinity during APC-catalyzed inactivation of factor VIIIa.


1997 ◽  
Vol 78 (03) ◽  
pp. 1030-1036 ◽  
Author(s):  
Lei Shea ◽  
Xuhua He ◽  
Björn Dahlbäck

SummaryHuman factor V has been shown not only to be a precursor to procoagulant factor Va but also to express anticoagulant properties. Thus, factor V was recently found to potentiate the effect of protein S as cofactor to activated protein C (APC) in the inactivation of the factor VIIIa-factor IXa complex. The purpose of this study was to determine whether the APC-cofactor function of factor V was also expressed in the bovine protein C system and to elucidate the molecular background for the species specificity of APC. For this purpose, the effects of protein S and factor V on APC-mediated inactivation of factor VIIIa were studied using purified APC, protein S and factor V of human and bovine.origin. The factor VIIIa investigated here was part of a Xase complex (i.e. factor IXa, factor VIIIa, phospholipid and calcium) and the APC-mediated inhibition of factor VIIIa was monitored by the ability of the Xase complex to activate factor X. Synergistic APC-cofactor function of factor V and protein S was demonstrated in the bovine system. The effect of bovine APC was potentiated by bovine protein S but not by human protein S, whereas both human or bovine protein S stimulated the function of human APC. Factor V did not express species specificity in its APC-cofactor activity even though bovine factor V was more potent than its human counterpart. Recombinant human/bovine protein S chimeras were used to demonstrate that the thrombin sensitive region and first epidermal growth factor-like module of protein S determine the species specificity of the APC-protein S interaction. In conclusion, both human and bovine factor V were found to express APC-cofactor activity which depends on the presence of protein S. The species specificity of APC was shown to be caused by the interaction between APC and protein S.


Blood ◽  
1994 ◽  
Vol 83 (11) ◽  
pp. 3120-3125 ◽  
Author(s):  
X Sun ◽  
B Evatt ◽  
JH Griffin

Abstract A coagulation test abnormality, termed activated protein C (APC) resistance, involving poor anticoagulant response to APC is currently the most common laboratory finding among venous thrombophilic patients. Because the anticoagulant activity of APC involves inactivation of factors Va and VIIIa, studies were made to assess the presence of abnormal factors V or VIII. Diluted aliquots of plasma from two unrelated patients with APC resistance and thrombosis were added to either factor VIII-deficient or factor V-deficient plasma and APC resistance assays were performed. The results suggested that patients' factor V but not factor VIII rendered the substrate plasma APC resistant. When factor V that had been partially purified from normal or APC resistant patients' plasmas using immunoaffinity chromatography was added to factor V-deficient plasma, APC resistance assays showed that patients' factor V or factor Va, but not normal factor V, rendered the substrate plasma resistant to APC. Studies of the inactivation of each partially purified thrombin-activated factor Va by APC suggested that half of the patients' factor Va was resistant to APC. These results support the hypothesis that the APC resistance of some venous thrombophilic plasmas is caused by abnormal factor Va.


Sign in / Sign up

Export Citation Format

Share Document